You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Changing Paradigms in Recurrent Clostridioides difficile Infection: Current and Emerging Microbiome-Directed Therapeutics

  • Authors: Paul Feuerstadt, MD, FACG, AGAF; Kevin W. Garey, PharmD; Mark Wilcox, MD
  • CME / ABIM MOC / CE Released: 6/30/2022
  • Valid for credit through: 6/30/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for infectious disease specialists, gastroenterologists, and primary care physicians.

The goal of this activity is that learners will be better able to discuss emerging treatments for recurrent CDI that target dysbiosis and how these therapies may be poised to alter the treatment landscape for this disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest data on emerging microbiome-directed therapeutics for recurrent C difficile infection
    • Risk factors for recurrent C difficile infection
  • Have greater competence related to
    • Management of a patient with recurrent C difficile infection


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Paul Feuerstadt, MD, FACG, AGAF

    Assistant Clinical Professor of Medicine
    Yale University School of Medicine
    Attending Gastroenterologist
    PACT-Gastroenterology Center
    Hamden, Connecticut, United States

    Disclosures

    Paul Feuerstadt, MD, FACG, AGAF, has the following relevant financial relationships:
    Consultant or advisor for: Ferring Pharmaceuticals; Merck & Co.; Seres Therapeutics; Takeda Pharmaceuticals
    Speaker or member of speakers bureau for: Ferring Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals
    Research funding from: Adare Pharmaceuticals; DaVolterra Pharmaceuticals; Ferring Pharmaceuticals; Finch Therapeutics; Seres Therapeutics

  • Kevin W. Garey, PharmD

    Professor of Pharmacy Practice
    Department Chair
    Pharmacy Practice and Translational Research
    University of Houston College of Pharmacy
    Houston, Texas, United States

    Disclosures

    Kevin W. Garey, PharmD, has the following relevant financial relationships:
    Research funding from: Acurx; Paratek Pharmaceuticals; Seres Therapeutics; Summit

  • Mark Wilcox, MD

    Professor of Medical Microbiology
    Sir Edward Brotherton Chair of Bacteriology
    Leeds Teaching Hospitals
    University of Leeds
    Leeds, United Kingdom

    Disclosures

    Mark Wilcox, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bayer; Crestone; DaVolterra Pharmaceuticals; Deinove; EnteroBiotix; Ferring Pharmaceuticals; GlaxoSmithKline; Merck; Nestle; Paion; Paratek Pharmaceuticals; Pfizer; Phico Therapeutics; Qpex; Biopharma; Seres Therapeutics; Summit; Surface Skins; Tillotts; Vaxxilon/Idorsia; Vedanta
    Speaker or member of speakers bureau for: GlaxoSmithKline; Merck; Pfizer; Seres
    Research funding from: Almirall; DaVolterra Pharmaceuticals; EnteroBiotix; GlaxoSmithKline; Merck; MicoPharm; Nabriva; Paratek Pharmaceuticals; Pfizer; Seres Therapeutics; Summit; Tillotts
    Stock options from: Seres Therapeutics

Editors

  • Roderick Smith, MS

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Roderick Smith, MS, has no relevant financial relationships.

  • Renata Feldman, PharmD

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Renata Feldman, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-22-195-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Changing Paradigms in Recurrent Clostridioides difficile Infection: Current and Emerging Microbiome-Directed Therapeutics

Authors: Paul Feuerstadt, MD, FACG, AGAF; Kevin W. Garey, PharmD; Mark Wilcox, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 6/30/2022

Valid for credit through: 6/30/2023

processing....

  • Print